Company: RGBP
Filing Date: 2025-05-28
Form Type: 10-Q
Source: 0001641172-25-012619
Chunk: 2

Company: Regen BioPharma Inc
Filing Date: 2025-05-28
Form: 10-Q
Item: Part I, Item 1
Chunk 2
---
723  
  Increase                                                                                       87,681                               ( 171  
  (Increase)                                                                                     76,008                               5,200  
  Increase                                                                                       287,053                                     
  Increase                                                                                       ( 63,280                          ( 78,407  
  (Gain)Loss                                                                                                                                 
  Unrealized                                                                                     -                                           
  Net                                                                                            ( 167,609                        ( 371,658  
  CASH                                                                                                                                       
  Increase                                                                                       -                                 ( 10,000  
  Increase                                                                                       168,655                           ( 61,500  
  Increase                                                                                       -                                  400,234  
  Net                                                                                            168,655                            328,734  
  Net                                                                                            1,045                             ( 42,924  
  Cash                                                                                           716                                121,037  
  Cash                                                                         $                 1,761          $                    78,114  
  Supplemental                                                                                                                               
  Common                                                                       $                 20,000         $                         -  
  Preferred                                                                    $                 -              $                         -  
  Cash                                                                         $                 -              $                         -  
  Common                                                                       $                 -              $                         -  
  Preferred                                                                    $                 -              $                         -  

The
Accompanying Notes are an Integral Part of These Financial Statements

   5  

REGEN
BIOPHARMA, INC.

Notes
to Condensed Consolidated Financial Statements

As
of March 31, 2025

These
Notes have been retroactively adjusted to reflect a 1 for 1500 reverse stock split of all issued series of stock effective as of March
6, 2023

1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The
Company was organized April 24, 2012 under the laws of the State of Nevada

The
Company intends to engage primarily in the development of regenerative medical applications which we intend to license from other entities
up to the point of successful completion of Phase I and or Phase II clinical trials after which we would either attempt to sell or license
those developed applications or, alternatively, advance the application further to Phase III clinical trials.

The
Company is currently engaged in actively identifying small molecules that inhibit or express NR2F6 leading to immune cell activation
for oncology applications and immune cell suppression for autoimmune disease.

The
Company is in the early stages of development of its proposed products and therapies. The Company will be required to obtain approval
from the FDA